Sanara MedTech Inc Dossier
Qualitative Analysis
Business overview
Sanara MedTech Inc. (NASDAQ: SMTI) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The company develops, markets, and distributes surgical products to surgeons at hospitals and ambulatory surgery centers, primarily selling in the North American surgical tissue repair market. Its core product portfolio includes CellerateRX Surgical Activated Collagen Adjuvant, BIASURGE Advanced Surgical Solution, and HemaQuell Resorbable Bone Hemostat. Following a strategic realignment in late 2025, Sanara divested and wound down its Tissue Health Plus (THP) chronic wound care segment to focus purely on its high-margin surgical business.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Executing commercial strategy to deepen penetration in the surgical wound market by expanding the contracted distributor network, growing the facility customer base, and adding new surgeon users within currently served facilities.
Expected impact: Sustained double-digit net revenue growth and increased market share in the North American surgical tissue repair market.
Strategic realignment to focus entirely on the high-margin, high-growth surgical business by winding down and discontinuing the unprofitable Tissue Health Plus (THP) segment.
Expected impact: Elimination of ongoing operational losses from THP, improved operating efficiency, and reallocation of capital to core surgical products.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquire advanced wound care diagnostic technologies, including a multispectral imager and biomarker assay, to help clinicians rapidly diagnose wound conditions and establish evidence-based treatment protocols.
Financial impact: Valued Precision Healing's equity at approximately $7.8 million (excluding shares already held by Sanara) consisting of $5.1 million in stock and cash consideration, plus the assumption of options and warrants.
Strategic Partnerships
Secured exclusive U.S. marketing, sales, and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive and related hardware-agnostic internal fixation delivery technology for fracture management.
Terms: Sanara agreed to contribute up to €8.0 million in cash (completed in 2025) in exchange for approximately 12.5% of BMI's outstanding equity. The license agreement is for an initial five-year period with automatic two-year renewals.